Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Zaman Huri, Hasniza ^a,b   Chai Ling, Lee ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Drug related problems; Dyslipidemia; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; DYSLIPIDEMIA; FEMALE; HUMAN; MALAYSIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALAYSIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890307378     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-1192     Document Type: Article

References (40)

1. Standard of medical care in diabetes. American Diabetes Association, Diabetes Care 2012 35 1 11 S63 22187469
2. Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes. Abstract 318. Fagot CA, Rolka DB, Beckles GL, Gregg EW, Narayan KM, Diabetes 2000 49 Supplement 1 78 A79
3. Dyslipidemia in type 2 diabetes mellitus. Mooradian SD, Nature Clin Pract: Endocrinol Metab 2009 5 3 150 159 10.1038/ncpendmet1066
4. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, BMJ 1998 316 823 828 10.1136/bmj.316.7134.823 9549452 (Pubitemid 28112428)
5. Pharmaceutical Care Network Europe Foundation, 2006, PCNE classification for drug-related problems version 5.01 2006 Retrieved October 22, 2011, from http://www.pcne.org/sig/drp/documents/PCNE%20classification%20V5.01.pdf
6. Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma: Interviewing patients at home. Haugbolle LS, Sorensen EW, Pharm World Sci 2006 28 239 247 10.1007/s11096-006-9023-9 17066246 (Pubitemid 44673752)
7. Development of an evidence-based checklist for the detection of drug-related problems in type 2 diabetes mellitus. Bob W, Ines K, Pharm World Sci 2009 31 580 595 10.1007/s11096-009-9312-1 19626455
8. Spectrum of liver disease in type 2 diabetes and the management of patients with diabetes and liver disease. Keith GT, Anthony D, Vivian F, Tan MH, Diabetes Care 2007 30 3 734 743 10.2337/dc06-1539 17327353 (Pubitemid 46354365)
9. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: A systematic literature review. Gunar S, Rosa LG, BioMed Central Nephrol 2011 12 35 1 12
10. Drug-related problems (DRP) identified from geriatric medication safety review clinics. Chan DC, Chen JH, Kuo HK, We CJ, Lu IS, Chiu LS, Wu SC, Arch Gerontol Geriatrics 2011 54 1 168 174
11. Contribution of drug-related problems to hospital admission in the elderly. Somers A, Robays H, Vander SR, Van MG, Bogaert M, Petrovic M, J Nutr Health Aging 2010 14 6 477 482 10.1007/s12603-009-0237-0 20617292
12. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. American Geriatrics Society, J Am Geriatr Soc 2012 1 16 doi: 10.1111/j.1532-5415.2012.03923.x
13. The status of diabetes control in Malaysia: Results of DiabCare 2008. Mafauzy M, Hussein Z, Chan SP, Medical J Malay 2011 66 3 175 181
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Cholesterol Education Program, JAMA 2001 285 19 2486 2497 10.1001/jama.285.19. 2486 11368702
15. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, Chen RS, Wong ND, Diabetes Res Clin Pract 2005 70 263 269 10.1016/j.diabres.2005.03.032 15890427 (Pubitemid 41539788)
16. Ministry of Health Malaysia, Clinical Practice Guidelines for: Management of Dyslipidemia 4 2011 Retrieved 13 October 2011, from http://www.acadmed.org. my/index.cfm?&menuid=67
17. Pharmacy: Misleading, but manageable. Reamer LB, Emily BM, Temple WS, Jane CA, Kit N, Clin Interv Aging 2008 3 2 383 389 18686760
18. Ministry of Health Malaysia, Clinical Practice Guidelines for: Management of type 2 diabetes mellitus 4 2009 Retrieved 11 October 2011, from http://www.acadmed.org.my/index.cfm?&menuid=67
19. Ministry of Health Malaysia, Clinical Practice Guidelines for: Management of Ischemic Stroke 2006 Retrieved 23 October 2011, from http://www.acadmed.org. my/index.cfm?&menuid=67
20. Ministry of Health Malaysia, Clinical Practice Guidelines for: Management of Hypertension 3 2008 Retrieved 23 October 2011, from http://www.acadmed.org. my/view-file.cfm?fileid=312
21. Lacy CF, Armstrong LL, Goldman MP, Lance LL, Drug Information Handbook Ohio: Lexi-Comp Inc 2011
22. British Medical Association & Royal Pharmaceutical Society, British National Formulary Edition 60 London: BMJ Group and Pharmaceutical Press 2010
23. Drug-related problems: Their structure and function. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD, Ann Pharmacother 1990 24 1093 1097
24. Drug-related problem: A cornerstone for pharmaceutical care. Foppe VM, J Malta College of Pharmacy Practice 2005 10 5 8
25. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Eichenberger PM, Lampert ML, Kahmann IV, van Mil JWF, Hersberger KE, Pharmaceut Weekblad Sci Ed 2010 32 3 362 372
26. Drug-related problems in diabetes and transplant patients: an observational study with home visits. Eichenberger PM, Haschke M, Lampert ML, Hersberger KE, Int J Clin Pharm 2011 33 5 815 823 10.1007/s11096-011-9542-x 21811831
27. Evaluating categorization and clinical relevance of drug-related problems in medication reviews. Granas AG, Berg C, Hjellvik V, Haukereid C, Kronstad A, Blix HS, Kilhovd B, Viktil KK, Horn AM, Pharm World Sci 2010 32 394 403 10.1007/s11096-010-9385-x 20407926
28. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K, Hypertens Res 2005 28 3 223 227 10.1291/hypres.28.223 16097365 (Pubitemid 40812606)
29. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Park CG, Lee H, Choi JW, Lee SJ, Kim SH, Lim HE, Intl J Clin Pharmacol Therapeut 2010 48 8 497 503 10.5414/CPP48497
30. Food and Drug Administration, FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury 2011 Retrieved January 3, 2012, from http://www.fda.gov/drugs/drugsafety/ucm256581.htm
31. Pharmaceutical care program for dyslipidemic patients at three primary health care centers: Impacts and outcomes. Lorenzo AV, Ana MVC, Carlos O, Paloma E, Maria EF, Marcela Q, Latin Am J Pharm 2009 28 3 415 420
32. Drug-related problems in hospitalized patients on polypharmacy: The influence of age and gender. Koh Y, Kutty FB, Li SC, J Therapeut Clin Risk Manag 2005 1 39 48 10.2147/tcrm.1.1.39.53597
33. The role of gender in compliance and attendance at an outpatient clinic for type 2 diabetes mellitus in Trinidad. Babwah F, Baksh S, Blake L, Cupid-Thuesday J, Hosein I, Sookhai A, Poon-King C, Hutchinson, Revista Panam Salud Publica 2006 19 2 79 84 (Pubitemid 44147360)
34. Gender differences in determinants and consequences of health and illness. Carol V, J Health Pop Nutrit 2007 25 1 47 61
35. Non-albuminuric renal impairment in type 2 diabetic patients and in the general population (National evaluation of the frequency of renal impairment coexisting with NIDDM (Nefron) 11). Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC, Diabetes Care 2009 32 8 1497 1502 10.2337/dc08-2186 19470839
36. Use of renal risk drugs in hospitalized patients with impaired renal function-an underestimated problem? Hege SB, Kirsten KV, Tron AM, Aasmund R, Nephrol Dialysis Transplant 2006 21 3164 3171 10.1093/ndt/gfl399 (Pubitemid 44567089)
37. Hyperlipidaemia in chronic kidney disease. Chan CM, Ann Acad Med Singapore 2005 35 31 35 (Pubitemid 40379970)
38. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Roger PA, Diabetes Spectrum 2006 19 1 13 16 10.2337/diaspect.19.1.13 (Pubitemid 43289890)
39. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Kirsten KV, Hege SB, Tron AM, Aasmund R, Brit J Clin Pharmacol. 2006 63 2187 2195
40. Role of triglyceride-rich lipoproteins in diabetic nephropathy. John CR, Kit FN, Hnin HA, Dennis WW, Nat Rev Nephrol 2010 6 361 370 10.1038/nrneph.2010. 59 20440276